Background: Parallel bodies of research suggest both a central role for osteoclasts in tumor-induced destruction of bone and the ability of biologic tumor necrosis factor-alpha (TNF-alpha) antagonists to attenuate the osteoclast-mediated bone destruction that accompanies a variety of nonmalignant disorders. Additional studies have implicated TNF-alpha in the promotion of osteoclast-mediated malignant osteolysis and the pathogenesis of neuropathic pain. TNF-alpha antagonists have the potential to interfere in both processes.
Objective: This article reviews the cases of 2 patients with treatment-refractory pain due to cancer metastases to bone who were given targeted injections of the biologic anti-TNF agent etanercept based on its potential to interfere directly with both malignant activation of osteoclasts and neuropathic pain.
Methods: One patient had a diagnosis of non-small cell lung cancer and the other had a diagnosis of breast cancer. Both presented with treatment-refractory pain due to bone metastases. The 2 patients received etanercept 25 mg by targeted SC injection in anatomic proximity to the site of spinal metastasis for relief of their treatment-refractory pain.
Results: Both patients experienced rapid, substantial, and sustained relief of chronic refractory pain at the treatment site after targeted administration of etanercept. Symptomatic improvement was correlated with objective measures of improvement, including weight gain in 1 patient and decreased uptake of radioactive tracer at the targeted site on positron emission tomography in the other.
Conclusions: Etanercept delivered by targeted SC injection may be of clinical benefit in selected patients with treatment-refractory pain caused by bone metastases. Clinical trials are needed to define the potential benefit of biologic TNF-alpha antagonists in the treatment and prevention of malignant osteolysis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0149-2918(03)80219-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mesalamine as treatment of neovaginal ileitis: Case report and review of literature.
J Pediatr Adolesc Gynecol
December 2024
Department of Obstetrics and Gynecology, Pediatric and Adolescent Gynecology Division, University of Washington, Seattle, WA 98109, USA. Electronic address:
Background: Neovaginal ileitis is an understudied complication of intestinal vaginoplasty for which no evidence-based treatments exist. Mesalamine has been successfully reported to treat neovaginal colitis and has mixed evidence of efficacy in treating ileal inflammatory syndromes.
Case: We report a 29-year-old female with a history of ileal neovaginoplasty at two years of age for cloacal variant and treatment-refractory neovaginal ileitis with pain and bleeding whose symptoms resolved with treatment with topical mesalamine.
Update Motility Disorders: Gastro-Oesophageal Reflux Disease - Diagnostic and Conservative Approach.
Visc Med
December 2024
Digestive Function: Basel, Laboratory and Clinic for Motility Disorders and Functional Digestive Diseases, Centre for Integrative Gastroenterology, Klinik Arlesheim, Arlesheim, Switzerland.
Background: Gastro-oesophageal reflux disease (GORD) is extremely common, with at least 1 in 10 people in the general population reporting heartburn and acid regurgitation on a weekly basis. GORD can also be associated with a variety of atypical symptoms, including chest pain, chronic cough, and laryngopharyngeal symptoms. The causes of GORD are multifactorial, and the severity of symptoms is influenced by peripheral and central factors, including psychosocial stress and anxiety.
View Article and Find Full Text PDFA transcutaneous electrical nerve stimulation device for the relief of neuropathic pain in NMOSD: A randomized, double-blind, sham-controlled trial.
Mult Scler J Exp Transl Clin
December 2024
Division of Neuroimmunology & Neuroinfectious Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Background: Individuals with neuromyelitis optica spectrum disorder (NMOSD) often suffer from severe, disabling, and treatment-refractory neuropathic pain. Transcutaneous electrical nerve stimulation (TENS) therapy is a non-invasive, pain-modifying device.
Objective: To determine whether TENS therapy is safe, tolerable, and effective for neuropathic pain in patients with NMOSD.
Characteristics and Management of Uncontrolled Gout Prior to Pegloticase Therapy: A 2-year Claims Analysis.
Rheumatol Ther
November 2024
Horizon Therapeutics (Now Amgen Inc.), 1 Horizon Way, Deerfield, IL, 60015, USA.
Article Synopsis
- Gout is a painful form of arthritis that can lead to more severe health issues when not properly treated; Pegloticase is a drug used to treat patients who do not respond to standard gout treatments.
- A study analyzed data from over 400 patients with chronic uncontrolled gout and found that their condition worsened significantly in the two years leading up to starting pegloticase therapy, with increases in gout-related symptoms and healthcare usage.
- The findings suggest that identifying and treating patients sooner could help reduce the complications and healthcare needs associated with uncontrolled gout.
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study.
Arthritis Res Ther
November 2024
Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR, USA.
Background: The efficacy and safety of upadacitinib in patients with ankylosing spondylitis (AS) and inadequate response/intolerance to biologic disease-modifying antirheumatic drugs (bDMARD-IR) were evaluated through 1 year in the SELECT-AXIS 2 study. Here, we assess 2-year efficacy, safety, and imaging outcomes in SELECT-AXIS 2.
Methods: Patients who received continuous upadacitinib, and those who switched from placebo to upadacitinib at week 14, could enter the open-label extension (OLE).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!